M. Schneider

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials

Anne Sophie Kubasch, Katharina Zoldan, Dominic Brauer, Philipp Kiewe et autres

BACKGROUND: Dysregulated innate immune signaling promotes inflammatory suppression of hematopoietic stem and progenitor cell function, contributing to ineffective erythropoiesis in myelodysplastic neoplasms (MDS). The phase 2, open-label CANFIRE and LUCAS trials aimed to determine the efficacy and safety of canakinumab or emavusertib, …

de, us, ch (code pays fourni par la source)

Pubertal Assessment and Growth in Patients With Hemoglobinopathies: A Longitudinal Multicenter Study on the Association With Ferritin Levels

Jill Dülberg, Concepción Prados Sánchez, Marie‐Anne Burckhardt, Lucía Alacán Friedrich et autres

OBJECTIVES: Although Advancements in the Treatment of Hemoglobinopathies have Considerably Increased Life Expectancy, Hormonal and Pubertal Development Have Been Continuously Affected by Complications From Transfusion-Related Iron Overload and Cytotoxic Therapies. This Study Investigated the Association Between Serum Ferritin Levels and Pubertal Progression …

ch, de, at (code pays fourni par la source)

Management des systemischen Lupus erythematodes – inklusive sekundärem Antiphospholipidsyndrom, Kinderwunsch und Schwangerschaft

Johanna Mücke, Hans‐Joachim Anders, Martin Aringer, Peter Berlit et autres

de, at, gr (code pays fourni par la source)

Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

Anne Sophie Kubasch, Katharina Zoldan, Michael Cross, M. Schneider et autres

Background Myelodysplastic neoplasms (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are hematologic malignancies characterized by dysfunctional hematopoiesis. These disorders frequently exhibit upregulation of inflammatory pathways, particularly those involving interleukin-1β (IL-1β) and interleukin-1 receptor-associated kinase 4 (IRAK4) within the bone marrow niche. This upregulation presents …

de (code pays fourni par la source)

1923P Real-world management and outcome of thymic carcinomas in a tertiary German center

Anca Margineanu, Maria Di Blasi, M. Hamilton, Farastuk Bozorgmehr et autres

de (code pays fourni par la source)

Altersabhängige Analyse des Einflusses der Makrophagen Polarisation von Brustkrebspatientinnen auf die postoperative Seromentstehung nach Mastektomie (SerMa-Pilotstudie)

F. Schneider, M. Köpke, C. Kühn, Carl Mathis Wild et autres

Zielsetzung: Die SerMa- Pilotstudie untersucht immunologische Faktoren der Serombildung nach Mastektomie und Erstdiagnose von Brustkrebs. In diesem Kontext lag ein besonderer Fokus auf CD68, einem spezifischen Marker für Tumor-assoziierte Makrophagen, sowie CD163, zum Nachweis M2-polarisierter Makrophagen. Beide beeinflussen Wundheilungsprozesse. Wir konnten bereits …

de, us (code pays fourni par la source)

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms

Susann Winter, M. Schneider, Uta Oelschlaegel, Giulia Maggioni et autres

Somatic mutations in the splicing factor SF3B1 occur in about one-third of all myelodysplastic neoplasms (MDS) and define a subgroup of patients characterized by ring sideroblasts (RS), ineffective erythropoiesis, and an indolent disease course in lower-risk (LR) MDS [ 1 ]. They …

de, gb, it (code pays fourni par la source)

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Anne Sophie Kubasch, Pierre Péterlin, Thomas Cluzeau, K. S. Götze et autres

Hypomethylating agents (HMAs) are the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS) and, in combination with venetoclax, for patients with acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy (IC) or allogeneic stem cell transplantation (alloSCT). Nevertheless, …

de, fr, nl (code pays fourni par la source)

Activation of distinct inflammatory pathways in subgroups of LR-MDS

M. Schneider, Clara Rolfs, Matthias Trumpp, Susann Winter et autres

Aberrant innate immune signaling has been identified as a potential key driver of the complex pathophysiology of myelodysplastic neoplasms (MDS). This study of a large, clinically and genetically well-characterized cohort of treatment-naïve MDS patients confirms intrinsic activation of inflammatory pathways in general …

de, us, ch (code pays fourni par la source)

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

M. Schneider, Clara Rolfs, Matthias Trumpp, Susann Winter et autres

Background Dysregulated innate immune signaling has been identified as a driver of the complex pathophysiology of myelodysplastic syndromes (MDS), predominantly in low risk (LR)-MDS (Basiorka et al., Blood 2016). The pharmacological targeting of inflammation may therefore help to retard disease development. However, …

de, ch (code pays fourni par la source)

Compartment-specific mutational landscape of clonal hematopoiesis

Luise Hartmann, Judith S. Hecker, Maja Rothenberg‐Thurley, Jennifer Rivière et autres

Clonal hematopoiesis (CH) is characterized by somatic mutations in blood cells of individuals without hematologic disease. While the mutational landscape of CH in peripheral blood (PB) has been well characterized, detailed analyses addressing its spatial and cellular distribution in the bone marrow …

de (code pays fourni par la source)

P747: LR-MDS IS CHARACTERIZED BY DIFFERENTIAL EXPRESSION OF INFLAMMASOME-RELATED GENES IN SPECIFIC CELL POPULATIONS

Clara Rolfs, M. Schneider, Matthias Trumpp, L. Fischer et autres

Background: Myelodysplastic Syndromes (MDS) are a group of hematopoietic neoplasms characterized by clonal expansion of hematopoietic stem and progenitor cells (HSPC) and peripheral blood cytopenia. MDS can develop from clonal hematopoiesis of indeterminate potential (CHIP) and progress through low-risk (LR) to high-risk …

de, ch, cn (code pays fourni par la source)